Eupraxia Pharmaceuticals Valuation
| EPRX Stock | CAD 7.01 0.19 2.64% |
At this time, the firm appears to be fairly valued. Eupraxia Pharmaceuticals shows a prevailing Real Value of C$6.8 per share. The current price of the firm is C$7.01. Our model computes the value of Eupraxia Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 264.03 M, shares owned by institutions of 6.00 %, and Shares Owned By Insiders of 19.12 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Eupraxia Pharmaceuticals' valuation include:
Fairly Valued
Today
Please note that Eupraxia Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Eupraxia Pharmaceuticals is based on 3 months time horizon. Increasing Eupraxia Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eupraxia Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eupraxia Stock. However, Eupraxia Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.01 | Real 6.8 | Hype 7.19 | Naive 6.3 |
The intrinsic value of Eupraxia Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eupraxia Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eupraxia Pharmaceuticals helps investors to forecast how Eupraxia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eupraxia Pharmaceuticals more accurately as focusing exclusively on Eupraxia Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Eupraxia Pharmaceuticals' intrinsic value based on its ongoing forecasts of Eupraxia Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Eupraxia Pharmaceuticals' closest peers.
Eupraxia Pharmaceuticals Cash |
|
Eupraxia Valuation Trend
Knowing Eupraxia Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Eupraxia Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Eupraxia Pharmaceuticals Total Value Analysis
Eupraxia Pharmaceuticals is currently estimated to have takeover price of 264.03 M with market capitalization of 251.3 M, debt of 1.54 M, and cash on hands of 35.46 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Eupraxia Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
264.03 M | 251.3 M | 1.54 M | 35.46 M |
Eupraxia Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Eupraxia is to check how much profit was generated for every dollar of assets it reports. Eupraxia Pharmaceuticals shows a negative utilization of assets of -0.52 percent, losing C$0.005206 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Eupraxia Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Eupraxia Pharmaceuticals Ownership Allocation
Eupraxia Pharmaceuticals holds a total of 35.85 Million outstanding shares. Eupraxia Pharmaceuticals shows 19.12 percent of its outstanding shares held by insiders and 6.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eupraxia Pharmaceuticals Profitability Analysis
Net Loss for the year was (25.74 M) with profit before overhead, payroll, taxes, and interest of 0.About Eupraxia Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Eupraxia Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eupraxia Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Eupraxia Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Eupraxia Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eupraxia Pharmaceuticals. We calculate exposure to Eupraxia Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eupraxia Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -188.9 K | -198.4 K |
Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.